Navigation Links
EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting

Supports Local Mechanism of Action of NP-1 in Neuropathic Pain

TARRYTOWN, N.Y., May 03, 2007 /PRNewswire-FirstCall/ -- EpiCept Corporation announced today that it will present new data for EpiCept(TM) NP-1 on Thursday, May 3, 2007 at the 26th Annual Scientific Meeting of the American Pain Society in Washington D.C. EpiCept NP-1 is a patented topical cream formulation of two FDA-approved drugs, 4% amitriptyline and 2% ketamine. NP-1 is a product candidate intended for use in the management of pain resulting from various peripheral neuropathies. Two studies will be presented in poster format by Dennis Everton, RPh., Director of Clinical Development.

Results from a new human pharmacokinetic study of NP-1 designed to assess the pharmacokinetic parameters as well as its safety and tolerability will be presented. The highest observed level of amitriptyline at any time point was 5.91 ng/mL. The highest observed level of ketamine at any time point was 10.7 ng/mL. These levels are far below any known systemic efficacy level and even further below any known systemic level associated with adverse reactions. The study found that NP-1 was safe and well tolerated across all age groups studied. The low systemic levels of amitriptyline and ketamine indicated a local mechanism of action rather than a systemic one. NP-1 is intended as additive therapy in neuropathic pain. This study confirms the independent topical mechanism of NP-1.

Findings will also be presented from a previously disclosed multicenter, double-blind, randomized, placebo controlled Phase II study of NP-1 in treating post-herpetic neuralgia (PHN) in 118 patients. The study was designed to evaluate the analgesic properties of two different strengths of NP-1 compared with placebo in the treatment of PHN. The study met its primary endpoint of an improvement in pain intensity for the high dose strength vs. placebo from baseline to day 21 (p=0.026). Add
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
2. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
4. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
5. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
6. The Past, Present and Future of HLA Typing
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
Post Your Comments:
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... SHANGHAI , Aug. 3 /PRNewswire-Asia/ -- Sangon ... company, and Bio Basic Inc. (BBI), a Toronto ... completion of,a $10 million round of funding ... scale research & development, marketing and sales of its ...
... Aug. 3 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services,Holdings Limited ... of the largest,network of radiotherapy and diagnostic imaging centers in ... for the second,quarter ended June 30, 2010 , before ... Medical,s management will hold an earnings conference call at ...
Cached Medicine Technology:Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 2Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 3Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010 2Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010 3
(Date:8/30/2014)... August 30, 2014 Continuing to meet ... is expanding with the addition of a new doctor ... who has provided leading-edge skin care in Grand Rapids ... , “As a doctor, my passion is making ... partnering with Forefront Dermatology, I’m better able to focus ...
(Date:8/30/2014)... Colorado Springs, CO (PRWEB) August 30, 2014 ... valuable, and increasingly difficult to get. Snoring and sleep apnea ... breathing stops) rob people and their bed partners of the ... Up to 45% of the population snores and 20 million ... these, only 10% have been diagnosed and treated; and of ...
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "My ... result of a car accident," said one of two ... muscle strain in her shoulder and neck area. She ... invented reduced pain and pressure, assisting in comfort and ... the patent-pending PILLOW CRADLE to support the head, neck ...
(Date:8/30/2014)... Market Research Report on Global and ... and in-depth market survey on Global and Chinese ... basic information of Lab Oven including its classification, ... global and China’s top manufacturers of Lab Oven ... market share etc. , The report further analyzes ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... development company in India, Profit By Outsourcing is ... Web Development services. The company gives emphasize on putting ... the complete product to clients. Their dedicated team of ... attaining ground-breaking results. They can handle even the critical ...
Breaking Medicine News(10 mins):Health News:Expanding Care at the Forefront of Dermatology 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2
... announced its approval for the use of DDT indoors, as ... pesticide, was banned// after it was found to be harmful ... Arata Kochi, director of the World Health Organization (WHO) malaria ... is indoor residual house spraying. Of the dozen pesticides WHO ...
... Studies presented at the 42nd Annual Meeting of the ... revealed that ACTOS? (pioglitazone HCl), an oral// antidiabetic medication, ... of heart attack and/or C and acute coronary syndrome ... disease (CVD) is the leading cause of premature death ...
... Researchers working closely with African American inner city ... problematic social incidents to help measure// which children ... ,"The girls preferred the cartoons over ... study leader Stephen S. Leff, Ph.D., a pediatric ...
... Hopkins has found that in addition to previously known ... of anemia in older adults, there// also exists ... ,"Our work supports the notion that mild anemia ... impairment in older adults," says Paulo Chaves, M.D., P.h.D., ...
... treatment for malaria has been developed with the help of ... in Africa. A system based on fluid// replacement for children ... in London in collaboration with the Wellcome Trust Kenya Medical ... of millions of kids, who die every year due to ...
... 1199NW has said that it supports the "Marty Smith" ... a partner when// they visit high-risk patients. Marty Smith ... of Larry Clark, a child rapist whose mother had ... his medications. ,Smith's case proves that mental ...
Cached Medicine News:Health News:ACTOS Linked to Several Cardiovascular Benefits 2Health News:ACTOS Linked to Several Cardiovascular Benefits 3Health News:ACTOS Linked to Several Cardiovascular Benefits 4Health News:Cartoons to Indicate Aggressiveness in Urban School Girls 2Health News:Cartoons to Indicate Aggressiveness in Urban School Girls 3Health News:Anemia Affects Both Body and Mind 2Health News:A Novel approach in Malaria treatment 2
... a hot air drying device for polyacrylamide and ... cellophane support for easy viewing. The assembly table ... surface for the drying frame. The dryer holds ... 115 V, 60 Hz system includes a gel ...
... The PRO6000 power supply ... Thermo's power supply product offering. ... proteomic and genomic electrophoresis. This ... to proteomic applications such as ...
The 570-90 is capable of producing up to 500 volts or 2,500 milliamps. It is an excellent choice for running all types of electroblotting applications. Also ideal for PAGE, SDS-PAGE, and DNA or RNA s...
... techniques such as submarine electrophoresis and SDS-PAGE, ... the Series 90 Programmable Power Supplies will ... Programmable Power Supplies are available in four ... All models operate in constant voltage, current ...
Medicine Products: